BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 31586988)

  • 41. Systematic profiling of a novel prognostic alternative splicing signature in hepatocellular carcinoma.
    Zhang D; Duan Y; Wang Z; Lin J
    Oncol Rep; 2019 Dec; 42(6):2450-2472. PubMed ID: 31578577
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of an alternative splicing signature as an independent factor in colon cancer.
    Chen H; Luo J; Guo J
    BMC Cancer; 2020 Sep; 20(1):904. PubMed ID: 32962686
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genome-Wide Profiling of Alternative Splicing Signatures Associated with Prognosis and Immune Microenvironment of Hepatocellular Carcinoma.
    Liu Z; Ye J; Khan AA; Chen J; Zhou L; Zheng S; Xu X
    Med Sci Monit; 2021 Aug; 27():e930052. PubMed ID: 34407065
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovering the molecular differences between right- and left-sided colon cancer using machine learning methods.
    Jiang Y; Yan X; Liu K; Shi Y; Wang C; Hu J; Li Y; Wu Q; Xiang M; Zhao R
    BMC Cancer; 2020 Oct; 20(1):1012. PubMed ID: 33076847
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of alternative splicing events in endometrial cancer prognosis.
    Liu J; Mi C; Long W; Sun T
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Jul; 46(7):680-688. PubMed ID: 34382583
    [TBL] [Abstract][Full Text] [Related]  

  • 46. RBM25 is a global splicing factor promoting inclusion of alternatively spliced exons and is itself regulated by lysine mono-methylation.
    Carlson SM; Soulette CM; Yang Z; Elias JE; Brooks AN; Gozani O
    J Biol Chem; 2017 Aug; 292(32):13381-13390. PubMed ID: 28655759
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Systematic analysis of survival-associated alternative splicing signatures in clear cell renal cell carcinoma.
    Chen T; Zheng W; Chen J; Lin S; Zou Z; Li X; Tan Z
    J Cell Biochem; 2020 Oct; 121(10):4074-4084. PubMed ID: 31886566
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of Alternative Splicing Events on Acute Myeloid Leukemia.
    Chen SL; Dai YJ; Hu F; Wang Y; Li H; Liang Y
    DNA Cell Biol; 2020 Nov; 39(11):2040-2051. PubMed ID: 32915082
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PCBP1 regulates the transcription and alternative splicing of metastasis‑related genes and pathways in hepatocellular carcinoma.
    Huang S; Luo K; Jiang L; Zhang XD; Lv YH; Li RF
    Sci Rep; 2021 Dec; 11(1):23356. PubMed ID: 34857818
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic index of aberrant mRNA splicing profiling acts as a predictive indicator for hepatocellular carcinoma based on TCGA SpliceSeq data.
    Wu HY; Peng ZG; He RQ; Luo B; Ma J; Hu XH; Dang YW; Chen G; Pan SL
    Int J Oncol; 2019 Aug; 55(2):425-438. PubMed ID: 31268164
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Analysis of alternative splicing events by RNA sequencing in the ovaries of Xiang pig at estrous and diestrous.
    Tang LT; Ran XQ; Mao N; Zhang FP; Niu X; Ruan YQ; Yi FL; Li S; Wang JF
    Theriogenology; 2018 Oct; 119():60-68. PubMed ID: 29982137
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characterization and prognostic significance of alternative splicing events in lower-grade diffuse gliomas.
    Zhao Z; Li GZ; Liu YQ; Huang RY; Wang KY; Jiang HY; Li RP; Chai RC; Zhang CB; Wu F
    J Cell Mol Med; 2020 Nov; 24(22):13171-13180. PubMed ID: 33006444
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Survival-Associated Alternative Messenger RNA Splicing Signatures in Pancreatic Ductal Adenocarcinoma: A Study Based on RNA-Sequencing Data.
    Zhou YJ; Zhu GQ; Zhang QW; Zheng KI; Chen JN; Zhang XT; Wang QW; Li XB
    DNA Cell Biol; 2019 Nov; 38(11):1207-1222. PubMed ID: 31483163
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comprehensive analysis of location-specific hub genes related to the pathogenesis of colon cancer.
    Shi C; Ding K; Li KZ; Long L; Li JL; Hu BL
    Med Oncol; 2020 Aug; 37(9):77. PubMed ID: 32743717
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Landscape of Alternative Splicing Events Related to Prognosis and Immune Infiltration in Glioma: A Data Analysis and Basic Verification.
    Su HX; Yang G; Su F; Hu CX; Zhang T; Ran JT; Guan QL
    J Immunol Res; 2022; 2022():2671891. PubMed ID: 35832652
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic Alternative mRNA Splicing in Adrenocortical Carcinoma.
    Liang W; Sun F
    Front Endocrinol (Lausanne); 2021; 12():538364. PubMed ID: 33776902
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The splicing factor SRSF6 is amplified and is an oncoprotein in lung and colon cancers.
    Cohen-Eliav M; Golan-Gerstl R; Siegfried Z; Andersen CL; Thorsen K; Ørntoft TF; Mu D; Karni R
    J Pathol; 2013 Mar; 229(4):630-9. PubMed ID: 23132731
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bioinformatic analysis of RNA-seq data from TCGA database reveals prognostic significance of immune-related genes in colon cancer.
    Ouyang Y; Huang J; Wang Y; Tang F; Hu Z; Zeng Z; Zhang S
    Medicine (Baltimore); 2022 Aug; 101(31):e29962. PubMed ID: 35945793
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A 65‑gene signature for prognostic prediction in colon adenocarcinoma.
    Jiang H; Du J; Gu J; Jin L; Pu Y; Fei B
    Int J Mol Med; 2018 Apr; 41(4):2021-2027. PubMed ID: 29393333
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Construction of prognostic predictor by comprehensive analyzing alternative splicing events for colon adenocarcinoma.
    Qu Y; Chen Y; Zhang L; Tian L
    World J Surg Oncol; 2020 Sep; 18(1):236. PubMed ID: 32883335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.